These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 25684541)

  • 21. Risk-adapted androgen deprivation and escalated three-dimensional conformal radiotherapy for prostate cancer: Does radiation dose influence outcome of patients treated with adjuvant androgen deprivation? A GICOR study.
    Zapatero A; Valcárcel F; Calvo FA; Algás R; Béjar A; Maldonado J; Villá S
    J Clin Oncol; 2005 Sep; 23(27):6561-8. PubMed ID: 16170164
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment outcome of high-dose image-guided intensity-modulated radiotherapy using intra-prostate fiducial markers for localized prostate cancer at a single institute in Japan.
    Takeda K; Takai Y; Narazaki K; Mitsuya M; Umezawa R; Kadoya N; Fujita Y; Sugawara T; Kubozono M; Shimizu E; Abe K; Shirata Y; Ishikawa Y; Yamamoto T; Kozumi M; Dobashi S; Matsushita H; Chida K; Ishidoya S; Arai Y; Jingu K; Yamada S
    Radiat Oncol; 2012 Jul; 7():105. PubMed ID: 22770471
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Excellent results from high dose rate brachytherapy and external beam for prostate cancer are not improved by androgen deprivation.
    Demanes DJ; Brandt D; Schour L; Hill DR
    Am J Clin Oncol; 2009 Aug; 32(4):342-7. PubMed ID: 19398902
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical toxicities and dosimetric parameters after whole-pelvis versus prostate-only intensity-modulated radiation therapy for prostate cancer.
    Deville C; Both S; Hwang WT; Tochner Z; Vapiwala N
    Int J Radiat Oncol Biol Phys; 2010 Nov; 78(3):763-72. PubMed ID: 20171807
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High-dose radiotherapy with helical tomotherapy and long-term androgen deprivation therapy for prostate cancer: 5-year outcomes.
    Tomita N; Soga N; Ogura Y; Hayashi N; Kageyama T; Ito M; Koide Y; Yoshida M; Kimura K; Makita C; Tachibana H; Kodaira T
    J Cancer Res Clin Oncol; 2016 Jul; 142(7):1609-19. PubMed ID: 27138879
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Improvement in prostate cancer survival over time: a 20-year analysis.
    Kim MM; Hoffman KE; Levy LB; Frank SJ; Pugh TJ; Choi S; Nguyen QN; McGuire SE; Lee AK; Kuban DA
    Cancer J; 2012; 18(1):1-8. PubMed ID: 22290249
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer.
    Zelefsky MJ; Chan H; Hunt M; Yamada Y; Shippy AM; Amols H
    J Urol; 2006 Oct; 176(4 Pt 1):1415-9. PubMed ID: 16952647
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Is androgen deprivation therapy necessary in all intermediate-risk prostate cancer patients treated in the dose escalation era?
    Castle KO; Hoffman KE; Levy LB; Lee AK; Choi S; Nguyen QN; Frank SJ; Pugh TJ; McGuire SE; Kuban DA
    Int J Radiat Oncol Biol Phys; 2013 Mar; 85(3):693-9. PubMed ID: 22836052
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Failure to achieve a PSA level Mitchell DM; McAleese J; Park RM; Stewart DP; Stranex S; Eakin RL; Houston RF; O'Sullivan JM
    Int J Radiat Oncol Biol Phys; 2007 Dec; 69(5):1467-71. PubMed ID: 17689886
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of androgen-deprivation therapy on the outcome of dose-escalation prostate cancer radiotherapy without elective pelvic irradiation.
    Hou WH; Huang CY; Wang CC; Lan KH; Chen CH; Yu HJ; Liu SP; Lai MK; Pu YS; Cheng JC
    Asian J Androl; 2017; 19(5):596-601. PubMed ID: 27506334
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Redefining high-risk prostate cancer based on distant metastases and mortality after high-dose radiotherapy with androgen deprivation therapy.
    Tendulkar RD; Reddy CA; Stephans KL; Ciezki JP; Klein EA; Mahadevan A; Kupelian PA
    Int J Radiat Oncol Biol Phys; 2012 Mar; 82(4):1397-404. PubMed ID: 21665379
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term survival and toxicity in patients treated with high-dose intensity modulated radiation therapy for localized prostate cancer.
    Spratt DE; Pei X; Yamada J; Kollmeier MA; Cox B; Zelefsky MJ
    Int J Radiat Oncol Biol Phys; 2013 Mar; 85(3):686-92. PubMed ID: 22795805
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hypofractionated simultaneous integrated boost (IMRT-SIB) with pelvic nodal irradiation and concurrent androgen deprivation therapy for high-risk prostate cancer: results of a prospective phase II trial.
    Magli A; Moretti E; Tullio A; Giannarini G; Tonetto F; Urpis M; Crespi M; Foti C; Prisco A; Polsinelli M; De Giorgi G; Bravo G; Scalchi P; Trovò M
    Prostate Cancer Prostatic Dis; 2018 Jun; 21(2):269-276. PubMed ID: 29520019
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hypofractionated boost to the dominant tumor region with intensity modulated stereotactic radiotherapy for prostate cancer: a sequential dose escalation pilot study.
    Miralbell R; Mollà M; Rouzaud M; Hidalgo A; Toscas JI; Lozano J; Sanz S; Ares C; Jorcano S; Linero D; Escudé L
    Int J Radiat Oncol Biol Phys; 2010 Sep; 78(1):50-7. PubMed ID: 19910135
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Late toxicity after intensity-modulated radiation therapy for localized prostate cancer: an exploration of dose-volume histogram parameters to limit genitourinary and gastrointestinal toxicity.
    Pederson AW; Fricano J; Correa D; Pelizzari CA; Liauw SL
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):235-41. PubMed ID: 21163587
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recurrence-free survival rates after external-beam radiotherapy for patients with clinical T1-T3 prostate carcinoma in the prostate-specific antigen era: what should we expect?
    Khuntia D; Reddy CA; Mahadevan A; Klein EA; Kupelian PA
    Cancer; 2004 Mar; 100(6):1283-92. PubMed ID: 15022298
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A pilot study of highly hypofractionated intensity-modulated radiation therapy over 3 weeks for localized prostate cancer.
    Nakamura K; Ikeda I; Inokuchi H; Takayama K; Inoue T; Kamba T; Ogawa O; Hiraoka M; Mizowaki T
    J Radiat Res; 2018 Sep; 59(5):656-663. PubMed ID: 30085048
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Outcome for Patients With Pathologic Node-Positive Prostate Cancer Treated With Intensity Modulated Radiation Therapy and Androgen Deprivation Therapy: A Case-Matched Analysis of pN1 and pN0 Patients.
    Van Hemelryk A; De Meerleer G; Ost P; Poelaert F; De Gersem W; Decaestecker K; De Visschere P; Fonteyne V
    Int J Radiat Oncol Biol Phys; 2016 Oct; 96(2):323-332. PubMed ID: 27598803
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and toxicity of intensity-modulated radiation therapy for prostate cancer in Chinese patients.
    Poon DM; Chan SL; Leung CM; Lee KM; Kam MK; Yu BK; Chan AT
    Hong Kong Med J; 2013 Oct; 19(5):407-15. PubMed ID: 23784530
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term results of conformal radiotherapy for prostate cancer: impact of dose escalation on biochemical tumor control and distant metastases-free survival outcomes.
    Zelefsky MJ; Yamada Y; Fuks Z; Zhang Z; Hunt M; Cahlon O; Park J; Shippy A
    Int J Radiat Oncol Biol Phys; 2008 Jul; 71(4):1028-33. PubMed ID: 18280056
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.